日韩av大片在线观看欧美成人不卡|午夜先锋看片|中国女人18毛片水多|免费xx高潮喷水|国产大片美女av|丰满老熟妇好大bbbbbbbbbbb|人妻上司四区|japanese人妻少妇乱中文|少妇做爰喷水高潮受不了|美女人妻被颜射的视频,亚洲国产精品久久艾草一,俄罗斯6一一11萝裸体自慰,午夜三级理论在线观看无码

深圳遠揚化學技術有限公司
中級會員 | 第10年

15012456311

托法替尼申報用雜質(zhì)

時間:2017/2/23閱讀:972
分享:

枸櫞酸托法替尼背景及作用機理:

枸櫞酸托法替尼是由美國輝瑞制藥公司開發(fā)一種治療類風濕關節(jié)炎藥物,,商品名Xeljanz,,用于對氨甲喋呤治療應答不充分或不耐受的中至重度活動性類風濕關節(jié)炎(RA)成人患者,。本產(chǎn)品是一種Janus激酶抑制劑,,每日服用兩次,。
2012年11月6日,,美國食品藥品管理局(FDA)和輝瑞公司聯(lián)合宣布,,枸櫞酸托法替尼獲準用于對氨甲喋呤治療應答不充分或不耐受的中至重度活動性類風濕關節(jié)炎(RA)成人患者,。
Xeljanz可作為單一治療或與氨甲喋呤或其他非生物疾病緩解性抗風濕藥物(DMARD)聯(lián)合使用。該藥不應與生物性DMARD或強免疫抑制劑(如硫唑嘌呤和環(huán)孢菌素)聯(lián)合使用,。經(jīng)核準的Xeljanz劑量為每日2次,,每次5mg,。

 

深圳遠揚化學可提供托法替尼申報所用全套雜質(zhì), 隨貨附CoA證書,,HNMR,,MS,HPLC圖譜,,純度符合申報要求,,托法替尼雜質(zhì)為我司優(yōu)勢雜質(zhì),長期備有庫存,,發(fā)貨快,。如需托法替尼雜質(zhì)相關詳細信息,歡迎我司業(yè)務人員獲取~

 

除自主品牌雜質(zhì)對照品外,,我司還代理英國NIBSC標準品,,美國劍橋CIL同位素標準品,美國NIST標準物質(zhì),,歐洲標準局IRMM標準物質(zhì),,加拿大TRC標準品,TLC標準品,,MOLCAN標準品,,NRC標準品等,歡迎洽談,。

 

附:托法替尼申報用雜質(zhì)列表:

Tofacitinib3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 1N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-1H-indol-4-amine
Tofacitinib Impurity 22-chloro-N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Tofacitinib Impurity 33-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 43-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 53-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxoprop*
Tofacitinib Impurity 63-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic acid
Tofacitinib Impurity 7N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Tofacitinib Impurity 8N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride
Tofacitinib Impurity 93-((3R,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile compound with 3-((3S,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (1:1)
Tofacitinib Impurity 103-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 11(3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride
Tofacitinib Impurity 12(3S,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride
Tofacitinib Impurity 13(3S,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride
Tofacitinib Impurity 14(3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride
Tofacitinib Impurity 153-((3R,4R)-3-(7H-[4,7'-bipyrrolo[2,3-d]pyrimidin]-4'-yl(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 16(3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carbaldehyde
Tofacitinib Impurity 17N-methyl-N-((3R,4R)-4-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Tofacitinib Impurity 183,3'-((3R,3'R,4R,4'R)-3,3'-((7H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)bis(methylazanediyl))bis(4-methylpiperidine-3,1-diyl))bis(3-oxopropanenitrile)
Tofacitinib Impurity 193-(4-(((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-oxopropanenitrile
Tofacitinib Impurity 203-((3R,4R)-3-((6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 21N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide
Tofacitinib Impurity 22(3R,4R)-1-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethylpiperidin-3-amine hydrochloride
Tofacitinib Impurity 23(3R,4R)-N,4-dimethyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine
Tofacitinib Impurity 24N-((3R,4R)-1,4-dimethylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride
Tofacitinib Impurity 251-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone
Tofacitinib Impurity 26N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine compound with N-((3S,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1:1)
Tofacitinib Impurity 27N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

 

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

X
您的留言已提交成功,!我們將在第一時間回復您~
撥打電話
在線留言